Sub arachnoid block failure
RandomForest as a Variable Selection Tool for Biomarker Data Katja Remlinger GlaxoSmithKline, RTP, NA ICSA Applied Statistics Symposium June 6 th, 2007.
Clinical Review Process: An FDA Perspective Karen Midthun, M.D. Deputy Director of Medicine Center for Biologics Evaluation and Research FDA April 15,
ILSI Health and Environmental Sciences Institute Syril D Pettit, MEM Executive Director February 25, 2015 Member Meeting HESI Washington, DC USA .
Application of Toxicology Databases in Drug Development (Estimating potential toxicity) Joseph F. Contrera, Ph.D. Director, Regulatory Research and Analysis.
DPC 083 ATAC Meeting Seattle February 24, 2002 Nancy Ruiz, MD.
DPC 083 ATAC Meeting Seattle February 24, 2002
1 Observations from the Antiviral Information Management System (AIMS) Database Jeffry Florian, Ph.D. CDER/OTS/OCP Division of Pharmacometrics, Reviewer.
1 Proton-Pump Inhibitor (PPI) Template for Pediatric Written Requests Pediatric Advisory Subcommittee of the Anti- Infective Drug Advisory Committee Hugo.
Receptor pharmacology or animal models for dose selection in humans? Bart Laurijssens Clinical Pharmacology Modelling & Simulation, GlaxoSmithKline, UK.
Overview of Targeted Therapies for Esophageal and Gastric Cancers Johanna Bendell, MD Director, GI Oncology Research Associate Director, Drug Development.
Application of Toxicology Databases in Drug Development (Estimating potential toxicity)
